ADVANCED THERAPIES WEEK 2023 MIAMI

Welcome to the press portal for Advanced Therapies Week - January 17th - 20th 2023 I Miami Beach Convention Center

Here you can find all the latest news direct from the conference; press releases, interviews from the floor, blog and video updates. Make sure to check in regularly.

We have a great list of media attending in person as well as covering remotely. Feel free to contact the team if you are a journalist or exhibitor and require any assistance during the show.

Advanced Therapies Week is an event like no other. Whether you’re looking for your next ground-breaking investment or searching for deeper topic understanding, Advanced Therapies Week is not to be missed. Bringing together the breadth of the industry and providing thought-provoking content, high-profile speakers, and unmissable networking events.

IB Communications is a leading international communications agency specialising in healthcare and life sciences. We hold specific expertise in the biotech and biopharma sectors, including immunotherapy, regenerative medicine, ATMPs and cell and gene therapy.

Press office contact: phacilitate@ibcomms.agency / +44 (0) 7707 560846.

Scroll down for latest news and press releases...

Press office contact: phacilitate@ibcomms.agency / +44 (0) 7707 560846.

Reaction from around the show

Please contact us if you believe there are mistakes in these videos - we'll do our best to rectify them ASAP

23Reactions

2023 Advanced Therapies Week - Press Releases

23releases

TrakCel and AmerisourceBergen expand platform integration to facilitate patient care coordination for cell and gene therapies.

Cardiff, UK, January 19, 2023 – TrakCel, the leading supplier of cellular orchestration solutions for clinical trials and commercial therapies to the cell and gene therapy (CGT) industry, and AmerisourceBergen, a global healthcare company, have expanded their platform integration capabilities to provide physicians and patient services teams more complete visibility across the treatment development and patient journey, enabling seamless care coordination and timely patient engagement.

Be The Match BioTherapies® Launches CIBMTR® CRO Services for Cell and Gene Therapy

MINNEAPOLIS, Minn. January 17, 2023 — Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced it is offering CIBMTR® (Center for International Blood and Marrow Transplant Research) Clinical Research Organization Services (CRO Services), which allows sponsors to significantly reduce the time required to launch and execute high-impact clinical trials. These CRO Services are a collaborative effort between Be The Match BioTherapies and the CIBMTR, resulting in unique expertise and access to unparalleled resources, including research, sites, donors, partnerships, and scientific and operational expertise.

Aldevron Launches Eureca-V™ MAD7®,

a Type-V CRISPR Nuclease

Research-Grade Product Launch Will Accelerate

CRISPR Research Worldwide, GMP Product to Follow

Center for Breakthrough Medicines Amplifies Viral Vector Manufacturing Capabilities by Licensing Asimov’s High-Performance GMP Suspension HEK293 Platform

King of Prussia, PA — January 18, 2023 — Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, announced today an agreement with Asimov, a Boston-based mammalian synthetic biology company building tools to design living systems, to license Asimov’s clonal HEK293 suspension cell line for the production of viral vectors.

Theragent Secures Novel Stem Cell Bank Production Contract with Accelerated Biosciences

Arcadia, CA (Jan. 2023) – Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer and rare disease treatments, has announced an agreement with Accelerated Biosciences, a regenerative medicine innovator, to produce the cGMP-grade master cell bank (MCB) for Accelerated Biosciences’ novel human Trophoblast Stem Cells (hTSCs).

Lonza Completes Expansion to Solid Form Services Facility at Bend (US) Site

The offering complements Lonza’s API development services and first-in-human services, aimed at the rapid advancement of small molecules

New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement

Basel, Switzerland, 16 January 2023 – Lonza today announces the completion of a planned expansion to its Solid Form Services (SFS) offering for small molecule drugs. The expanded facility in Bend, Oregon (US) became fully operational in Q4 2022, enhancing Lonza's capabilities in meeting accelerated timelines for increasingly complex molecules.

AABB INTRODUCES NEW BIOTHERAPIES CORPORATE MEMBERSHIP PROGRAM

BETHESDA, Md. – The Association for the Advancement of Blood & Biotherapies (AABB) is proud to introduce the AABB Biotherapies Corporate Membership Program, an initiative designed to ease challenges that biotherapies companies face, including workforce development, quality systems control and regulatory support.

Avectas Launches the Solupore® platform for the clinical manufacturing of next- generation gene-modified cell therapies with unparalleled cell health and functionality

DUBLIN, Ireland and CAMBRIDGE, MA – 16 January 2023: Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week, Miami Beach Convention Centre, January 17th - 20th, 2023, Booth # 331

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

Newark, New Jersey – January 17, 2022 – BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they have successfully completed tech transfer of AVB-001 from client Avenge Bio and initiated manufacturing of clinical grade material, which will support Avenge Bio’s ongoing phase 1/2 clinical trial.

MicrofluidX and CCRM partner on end-to-end bioprocessing of CAR-T cell therapies

Excellos Launches ‘Excellos 360’ Alongside RUO and

GMP Product Portfolio to Reduce Clinical Response

Variability

January 17, 2023; San Diego, California – Excellos, the California-based, full-service CDMO, has today announced the launch of ‘Excellos 360’, a new service offering, at Phacilitate’s Advanced Therapies Week in Miami.